Search Results

You are looking at 1 - 10 of 21 items for :

  • lanreotide Autogel x
  • Refine by Access: All content x
Clear All
Open access

Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski, and on behalf of the CLARINET Investigators

Introduction CLARINET was a landmark 96-week study that confirmed anti-tumour effects for the long-acting somatostatin analogue lanreotide Autogel (depot in the USA) 120 mg. Lanreotide prolonged progression-free survival (PFS) over placebo in

Free access

Kjell Öberg and Steven W J Lamberts

lanreotide Autogel, the first available sustained-release formulation based on self-assembling nanotube technology ( Fig. 1 ) ( Pouget et al . 2010 ). After administration, lanreotide peptide monomers are slowly released from the ends of the nanotubes over a

Open access

Jonathan R Strosberg, James C Yao, Emilio Bajetta, Mounir Aout, Bert Bakker, John D Hainsworth, Philippe B Ruszniewski, Eric Van Cutsem, Kjell Öberg, and Marianne E Pavel

), patients with advanced NET treated with lanreotide autogel (120 mg via deep s.c. injection every 28 days) also had improvement in progression-free survival (PFS) when compared with placebo (PFS, not reached (NR) vs 18 months and HR, 0.47; 95% Cl 0

Free access

Iulia Potorac, Patrick Petrossians, Adrian F Daly, Orsalia Alexopoulou, Sophie Borot, Mona Sahnoun-Fathallah, Frederic Castinetti, France Devuyst, Marie-Lise Jaffrain-Rea, Claire Briet, Florina Luca, Marion Lapoirie, Flavius Zoicas, Isabelle Simoneau, Alpha M Diallo, Ammar Muhammad, Fahrettin Kelestimur, Elena Nazzari, Rogelio Garcia Centeno, Susan M Webb, Marie-Laure Nunes, Vaclav Hana, Véronique Pascal-Vigneron, Irena Ilovayskaya, Farida Nasybullina, Samia Achir, Diego Ferone, Sebastian J C M M Neggers, Brigitte Delemer, Jean-Michel Petit, Christof Schöfl, Gerald Raverot, Bernard Goichot, Patrice Rodien, Bernard Corvilain, Thierry Brue, Franck Schillo, Luaba Tshibanda, Dominique Maiter, Jean-François Bonneville, and Albert Beckers

received lanreotide Autogel (among these, one was switched to octreotide LAR), 69 patients received octreotide LAR (among them, two were switched to lanreotide Autogel) and three received pasireotide. For three patients, the SSA dose used was unknown. The

Free access

Johannes Hofland, Aura D Herrera-Martínez, Wouter T Zandee, and Wouter W de Herder

-blind placebo-controlled trials studying the antiproliferative effects of octreotide LAR and lanreotide autogel led to the world-wide registration of these drugs as antiproliferative agents in NET patients. However, the PROMID study ( Rinke et al. 2009

Free access

Mohid S Khan and Martyn E Caplin

studies of which are shown in Table 2 . The development of long-acting depot formulations, octreotide LAR and lanreotide Autogel, has allowed clinically practical administration of these drugs by i.m. and deep s.c. routes every 28 days. Biochemical

Open access

Dimitrios Papantoniou, Malin Grönberg, Espen Thiis-Evensen, Halfdan Sorbye, Kalle Landerholm, Staffan Welin, and Eva Tiensuu Janson

2014 , Lamberti et al. 2020 , Diamantopoulos et al. 2021 ). A prospective phase 2 trial (CLARINET FORTE) with above-label dose of lanreotide autogel recently reported moderate efficacy, with a median PFS of 8.3 months in the Si-NET subgroup. Only

Free access

Georgios K Dimitriadis, Martin O Weickert, Harpal S Randeva, Gregory Kaltsas, and Ashley Grossman

-acting formulation, the most convenient being lanreotide autogel (Ipsen). Long-acting SSAs (octreotide and lanreotide) are the best available option for symptom relief from secretory tumours bearing SSTRs on their surface, irrespective of the secretory components

Free access

Omar Abdel-Rahman, Angela Lamarca, Juan W Valle, and Richard A Hubner

-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study. ASCO 2014 Annual Meeting . Journal of Clinical Oncology 32 (May 20 Supplement) abstract 4107 Cebon J Findlay M Hargreaves C

Free access

Simona Grozinsky-Glasberg, Ilan Shimon, Márta Korbonits, and Ashley B Grossman

compound (about 3 min in blood) has resulted in the development of synthetic analogues: short acting (octreotide, which needs to be administered subcutaneously several times per day) or long acting (octreotide long-acting release, LAR and lanreotide autogel